Lauder R&D
This article was originally published in The Rose Sheet
Executive Summary
The Estee Lauder Companies Innovation Institute opens in Shanghai, China, representing an investment in market-specific research and development in the region, firm announces Nov. 22. The 857-square-meter facility will focus on biological and physical sciences, with researchers studying "the safety and efficacy of topical botanical and synthetic materials and...the genetic basis for differences in the response of human skin to environmental stressors," company says. Institute will work with dermatologists and other research organization on "cutting edge" projects, develop local unique raw materials inspired by traditional Chinese medicine and work with the firm's global R&D group to achieve "tailor made, high quality products for the Asian consumer," firm adds. New facility is the seventh in the company's history and the second largest in Asia, according to Lauder...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.